Novocure Stock Price, News & Analysis

Novocure (NASDAQ: NVCR) appointed Frank Leonard as Chief Executive Officer effective December 1, 2025, succeeding Ashley Cordova who resigned. Mr. Leonard is a 15+ year Novocure veteran who previously served as company president and led global sales, marketing, field medical affairs, patient experience, public affairs, market access, and product and portfolio strategy.

The board highlighted Mr. Leonard’s role preparing Novocure’s first commercial launch and establishing finance, reimbursement, and business development functions. Mr. Leonard said he will focus on launching products in new indications, completing multiple clinical trials, and advancing the company’s device-based cancer therapy.

Novocure (NASDAQ: NVCR) said management will participate in the 37th Annual Piper Sandler Healthcare Conference in New York on Tuesday, December 2, 2025.

William Doyle, Executive Chairman, will take part in a fireside chat at 11:30 a.m. ET and hold one-on-one investor meetings during the event. A live audio webcast of the presentation will be available on the company Investor Relations site and replayable for at least 14 days after the event.

Novocure (NASDAQ: NVCR) management will participate in the Jefferies Global Healthcare Conference in London on Wednesday, November 19, 2025. Ashley Cordova, CEO, will present at 2:00 p.m. GMT (9:00 a.m. ET), and CFO Christoph Brackmann will join for one-on-one investor meetings. A live audio webcast will be available from Novocure's Investor Relations page and available for replay for at least 14 days after the event.

Novocure (NASDAQ: NVCR) reported Q3 2025 results: quarterly net revenues of $167.2 million (up 8% YoY) and 4,416 active patients as of September 30, 2025. Gross margin was 73%. The company reported a net loss of $37.3 million and adjusted EBITDA of $(3.0) million. Cash, cash equivalents and short-term investments totaled $1,033.5 million.

Regulatory and clinical updates: the FDA accepted the PMA filing for TTFields in locally advanced pancreatic cancer; Optune Lua received Japanese approval for use with PD-1/PD-L1 inhibitors in advanced NSCLC; several clinical readouts are expected in 2026.

Novocure (NASDAQ: NVCR) will present new pre-clinical and clinical research at two oncology congresses in October 2025: the EANO Meeting in Prague (Oct 16-19) and the ESMO Congress in Berlin (Oct 17-21).

At EANO (Poster P18.24.B, Oct 18, 5:00-6:30 PM CEST) Novocure will present pre-clinical data showing that short exposure to TTFields downregulates DNA repair pathways and may radiosensitize glioblastoma cells. At ESMO (Poster 2235P, Oct 19, 12:00-12:45 PM CEST) Novocure will present a post-hoc analysis from the Phase 3 PANOVA-3 trial evaluating TTFields plus gemcitabine/nab-paclitaxel versus chemotherapy alone in unresectable, locally advanced pancreatic adenocarcinoma, analyzing outcomes by device usage and CA 19-9 levels.

Novocure (NASDAQ: NVCR) has scheduled its third quarter 2025 financial results announcement for October 30, 2025, before U.S. markets open. The company will host a conference call and webcast at 8:00 a.m. EDT on the same day to discuss financial results for both the three and nine-month periods ending September 30, 2025.

Investors can access presentation slides and the corporate presentation through Novocure's investor relations website, which will remain available for at least 14 days after the call. The company uses its investor relations website to disclose material non-public information in compliance with Regulation FD.

Novocure (NASDAQ: NVCR) announced positive final results from its pivotal Phase 3 METIS trial evaluating Tumor Treating Fields (TTFields) therapy for brain metastases from non-small cell lung cancer (NSCLC). The trial met its primary endpoint, demonstrating a statistically significant delay in time to intracranial progression.

Key findings include a 28% lower risk of intracranial progression in patients receiving TTFields therapy with best supportive care (BSC) versus BSC alone. The median time to intracranial progression was 15.0 months for TTFields therapy compared to 7.5 months for BSC alone. The therapy showed enhanced benefits in patients receiving immune checkpoint inhibitors, with no negative impact on quality of life or neurocognition.

Novocure (NASDAQ: NVCR) has received approval from Japan's Ministry of Health, Labour and Welfare for Optune Lua® to treat unresectable advanced/recurrent non-small cell lung cancer (NSCLC). The approval is for concurrent use with PD-1/PD-L1 inhibitors in adult patients who have progressed after platinum-based chemotherapy.

The approval is backed by the Phase 3 LUNAR trial results, which demonstrated a significant 3.3-month improvement in median overall survival (13.2 months vs. 9.9 months) in the experimental arm. Notably, patients receiving Optune Lua with PD-1/PD-L1 inhibitors showed an impressive 8.0-month survival benefit (19.0 months vs. 10.8 months, P=0.02).

The device showed a favorable safety profile, with primarily low-grade skin-related events and no Grade 4 or 5 toxicities reported.

Novocure (NASDAQ: NVCR) has announced its participation in three major investor conferences in September 2025. CEO Ashley Cordova will lead fireside chats at the Wells Fargo Healthcare Conference (Sept. 4), H.C. Wainwright Global Investment Conference (Sept. 9), and Morgan Stanley Global Healthcare Conference (Sept. 10).

CFO Christoph Brackmann will join for investor meetings at the H.C. Wainwright and Morgan Stanley events. All presentations will be available via webcast on Novocure's investor relations website for at least 14 days after each event.